Blog Archives

NEW FRAMEWORK MEASURES FAIRNESS WHEN DISTRIBUTING VACCINES

Blacksburg, VA, USA – When vaccines are in short supply, public health officials must decide who among the public should be protected against disease – a decision that can hold moral and ethical implications. In order to avoid such concerns,

Tagged with: , , , , , ,
Posted in Announcements, Health Policy Analyses

SUCCESS FEE: A NOVEL TOOL FOR THE SUSTAINABILITY OF NOVEL EXPENSIVE THERAPIES

Catania, Italy – To guarantee rapid patient access to high cost, innovative therapies, policy makers have introduced cost-containment strategies based on the partial or total reimbursements of a drug price. Under these agreements, market access for a drug is granted

Tagged with: , , , , , , ,
Posted in Announcements, Policy Perspectives, Value in Health

THE IMPACT OF PRICE REDUCTIONS AND COST-SHARING RATES IN GREECE

Athens, Greece – Public expenditure on pharmaceuticals in Greece is high (compared to other EU countries) and has increased by 73%, from €3 billion in 2005 to €5.2 billion in 2009. Since 2010, cost containment efforts focused on the reduction

Tagged with: , , ,
Posted in Health Policy Analyses, Value in Health Regional Issues

¿LA EVALUACIÓN DE INSUMOS, IMPACTA EN LA OPTIMIZACIÓN DE RECURSOS?

México, D.F. – En México, se fortaleció el proceso de actualización de medicamentos del  Cuadro Básico y Catálogo de Insumos del Sector Salud (CBCISS), estandarizando criterios de selección, basados en evidencia clínica-epidemiológica-económica. 

Tagged with: , ,
Posted in Health Policy Analyses, Value in Health Regional Issues

¿LA EVALUACIÓN DE INSUMOS, IMPACTA EN LA OPTIMIZACIÓN DE RECURSOS?

México, D.F. – En México, se fortaleció el proceso de actualización de medicamentos del  Cuadro Básico y Catálogo de Insumos del Sector Salud (CBCISS), estandarizando criterios de selección, basados en evidencia clínica-epidemiológica-económica.

Tagged with: ,
Posted in Health Policy Analyses, Value in Health Regional Issues

Subgrouping Practice in Early Benefit Assessment in Germany Risks Misusing Evidence-based Medicine

Hannover, Germany – Since 2011, the German AMNOG (Act on the Reform of the Market for Medicinal Products) legislation regulates drug reimbursement in an attempt to reduce national health care costs. The Federal Joint Committee (G-BA) and the Institute for Quality

Tagged with: , , , , ,
Posted in Commentary, Value in Health

A New Approach To Korea’s Reimbursement Coverage And Pricing Rules For Medical Devices Long Overdue

Seoul, South Korea – Since 1989, Korea has had a comprehensive National Health Insurance system, which also covers most implantable and disposable medical devices. Although medical devices account for only about 4% of the total budget, considerable attention is paid to

Tagged with: , , , , ,
Posted in Policy Perspectives, Value in Health

Improving Clinical Trial Participation Through Patient-Centered Trial Design

Baltimore, MD, USA – Many people are reluctant to participate in clinical trials.  This reluctance stems from the perception of risk while not seeing any clear benefit to participation.  The exception is when an individual has a condition for which there

Tagged with: , , , , ,
Posted in Policy Perspectives, Value in Health

Issues And Challenges When Pharma Works With Regulators & HTA Agencies

Canberra, Australia – The pivotal phase III clinical trials for new medicines are designed to support their registration, yet they are also used to support their reimbursement and pricing. The clinical evidence needs of HTA agencies (payers) are often different than

Tagged with: , , ,
Posted in Health Policy Analyses, Value in Health

Nice’s Scientific Credibility Compromised By Recent Amendment To Appraisal Methods

Toronto, ON, Canada – The National Institute for Health and Care Excellence (NICE) is highly regarded for the rigorous methods it adopts for the economic appraisal of health care technologies. A recent amendment to these appraisal methods, however, raises a number

Tagged with: , , , ,
Posted in Commentary, Value in Health
Categories
Follow ISPOR
RSS FeedFriend me on FacebookFollow my company on LinkedInFollow me on TwitterWatch me on YouTube